A 33-day-old female with an ulcerated infantile hemangioma (IH) undergoing oral therapy with propranolol 2 mg/kg per day developed hyperkalemia and hyperphosphatemia 24 h after starting medication. No electrocardiographic or clinical abnormalities secondary to the electrolyte changes were noticed. A laboratory tumor lysis syndrome (TLS) was diagnosed after excluding other causes of electrolyte imbalance in the diagnostic workup. No treatment was required to reverse the TLS condition, and the propranolol therapy was continued as the electrolyte alterations were only mild. One month later, the IH was remarkably reduced in size and no longer ulcerated. Maintenance of propranolol was extended for a total of 6 months. Parallel to the gradual involution of the IH, serum potassium and phosphorus levels returned within normal levels. We suggest that TLS may be a rare complication of ulcerated IH treated with propranolol. Clinicians must be aware and order appropriate screening tests for TLS in patients at risk.

Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo J-B, Taïeb A: Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;17:2649–2651.
Hogeling M, Adams S, Wargon O: A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011;128:e259–266.
Zimmermann AP, Wiegand S, Werner JA, Eivazi B: Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinol 2010;74:338–342.
Storch CH, Hoeger PH: Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010;163:269–274.
Coiffier B, Altman A, Pui CH, Younes A, Cairo MS: Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008;26:2767–2778.
Murad MH, Coto-Yglesias F, Wang AT, et al: Clinical review: drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab 2009;94:741–745.
Holland KE, Frieden IJ, Frommelt PC, et al: Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol 2010;146:775–778.
Pavlakovic H, Kietz S, Lauerer P, Zutt M, Lakomek M: Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Pediatrics 2010;126:e1589–e1593.
Rosa RM, Silva P, Young JB, et al: Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 1980;302:431–434.
Brown RS: Extrarenal potassium homeostasis. Kidney Int 1986;30:116–127.
Hayward LJ, Kim JS, Ming-Yang L, et al: Targeted mutation of mouse skeletal muscle sodium channel produces myotonia and potassium-sensitive weakness. J Clin Invest 2008;118:1437–1449.
Tannock I: Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 1978;62:1117–1133.
Jona JZ: Progressive tumor necrosis and lethal hyperkalemia in a neonate with sacrococcygeal teratoma (SCT). J Perinatol 1999;19:538–540.
Chang LC, Haggstrom AN, Drolet BA, et al: Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008;122:360–367.
Thomas RF, Hornung RL, Manning SC, et al: Hemangiomas of infancy: treatment of ulceration in the head and neck. Arch Facial Plast Surg 2005;7:312–315.
Saint-Jean M, Léauté-Labrèze C, Mazereeuw-Hautier J, Bodak N, Hamel-Teillac D, et al: Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol 2011;64:827–832.
Kim LHC, Hogeling M, Wargon O, Jiwane A, Adams S: Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. J Pediatr Surg 2011;46:759–763.
Pandey A, Gangopadhyay AN, Sharma SP, et al: Conservative management of ulcerated haemangioma – twenty years’ experience. Int Wound J 2009;6:59–62.
Metz BJ, Rubenstein MC, Levy ML, et al: Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol 2004;140:867–870.
Cairo MS, Bishop M: Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3–11.
Davidson MB, Thakkar S, Hix JK, et al: Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004;116:546–554.
Bishop MR, Cairo MS, Coccia PF: Tumor lysis syndrome; in Abeloff MD (ed): Clinical Oncology, ed 3. Philadelphia, Elsevier/Churchill Livingstone, 2004, pp 987–992.
Rheingold S, Lange B: Oncologic emergencies; in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology, ed 5. Philadelphia, Lippincott Williams & Wilkins, 2006, pp 1202–1230.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.